LEXINGTON, MA, USA I September 29, 2015 I Aldeyra Therapeutics, Inc. (ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced that it has enrolled the first patient in a Phase IIa clinical trial of NS2 for the treatment of allergic conjunctivitis.
Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, commented, “With the first patient enrolled in our allergic conjunctivitis Phase IIa trial, we are now actively studying NS2 in three indications. Over the past year, we have made tremendous progress in expanding the clinical development of NS2, adding to the number of opportunities to demonstrate the potential of our novel therapeutic in the treatment of diseases thought to be mediated by aldehydes.”
A synopsis of the trial is expected to be available on www.clinicaltrials.gov within 21 days.
About NS2
NS2 is an aldehyde-binding small molecule based on an innovative platform technology focused on trapping free aldehydes, which are toxic and pro-inflammatory mediators of numerous diseases. By decreasing aldehyde load, NS2 may mitigate excessive inflammation and address diseases where aldehydes are thought to mediate pathology.
About Allergic Conjunctivitise
Allergic conjunctivitis is a common disease that is thought to be mediated in part by pro-inflammatory aldehydes, and is characterized by inflammation of the conjunctiva (a membrane covering part of the front of the eye), resulting in excessive tear production in addition to ocular swelling, redness, and itching.
About Aldeyra Therapeutics
Aldeyra Therapeutics, Inc., is a biotechnology company focused primarily on the development of products to treat diseases thought to be related to endogenous aldehydes, a naturally occurring class of toxic molecules. The company has developed NS2, a product candidate designed to trap free aldehydes. Aldeyra has initiated clinical testing of NS2 for the treatment of Sjogren-Larsson Syndrome, noninfectious anterior uveitis, and allergic conjunctivitis. NS2 has not been approved for sale in the U.S. or elsewhere. www.aldeyra.com.
SOURCE: Aldeyra Therapeutics
Post Views: 105
LEXINGTON, MA, USA I September 29, 2015 I Aldeyra Therapeutics, Inc. (ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced that it has enrolled the first patient in a Phase IIa clinical trial of NS2 for the treatment of allergic conjunctivitis.
Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, commented, “With the first patient enrolled in our allergic conjunctivitis Phase IIa trial, we are now actively studying NS2 in three indications. Over the past year, we have made tremendous progress in expanding the clinical development of NS2, adding to the number of opportunities to demonstrate the potential of our novel therapeutic in the treatment of diseases thought to be mediated by aldehydes.”
A synopsis of the trial is expected to be available on www.clinicaltrials.gov within 21 days.
About NS2
NS2 is an aldehyde-binding small molecule based on an innovative platform technology focused on trapping free aldehydes, which are toxic and pro-inflammatory mediators of numerous diseases. By decreasing aldehyde load, NS2 may mitigate excessive inflammation and address diseases where aldehydes are thought to mediate pathology.
About Allergic Conjunctivitise
Allergic conjunctivitis is a common disease that is thought to be mediated in part by pro-inflammatory aldehydes, and is characterized by inflammation of the conjunctiva (a membrane covering part of the front of the eye), resulting in excessive tear production in addition to ocular swelling, redness, and itching.
About Aldeyra Therapeutics
Aldeyra Therapeutics, Inc., is a biotechnology company focused primarily on the development of products to treat diseases thought to be related to endogenous aldehydes, a naturally occurring class of toxic molecules. The company has developed NS2, a product candidate designed to trap free aldehydes. Aldeyra has initiated clinical testing of NS2 for the treatment of Sjogren-Larsson Syndrome, noninfectious anterior uveitis, and allergic conjunctivitis. NS2 has not been approved for sale in the U.S. or elsewhere. www.aldeyra.com.
SOURCE: Aldeyra Therapeutics
Post Views: 105
